JAK inhibitor: tofacitinib, a new disease modifying anti-rheumatic drug

• Yamaoka Kunihiro

  The First Department of Internal Medicine, University of Occupational and Environmental Health, Fukuoka, Japan

• Kubo Satoshi

  The First Department of Internal Medicine, University of Occupational and Environmental Health, Fukuoka, Japan

• Sonomoto Koshiro

  The First Department of Internal Medicine, University of Occupational and Environmental Health, Fukuoka, Japan

• Maeshima Keisuke

  Department of Internal Medicine I, Faculty of Medicine, Oita University, Oita, Japan

• Tanaka Yoshiya

  The First Department of Internal Medicine, University of Occupational and Environmental Health, Fukuoka, Japan

抄録

Treatment of rheumatoid arthritis (RA) with biologic agents targeting inflammatory cytokines and cell surface molecules such as tumor necrosis factor and Interleukin-6 is generally more efficacious than traditional disease-modifying antirheumatic drugs when combined with MTX. However, not only do ∼30% of patients poorly respond to treatment but also parenteral mode of administration and expense are issues to be solved. Recently, a kinase inhibitor targeting Janus kinases (JAKs), has shown high efficacy in active RA in clinical trials. Among several JAK inhibitors in clinical trials for RA, tofacitinib is a step ahead for use in clinical practice. Kinase inhibitors are orally available, which is a major advantage over biologic agents, in addition to being less expensive. This review describes recent advance in JAK inhibitors for RA and its possible mechanism of action.

収録刊行物

• Inflammation and Regeneration

  Inflammation and Regeneration 31 (4), 349-353, 2011

  一般社団法人 日本炎症・再生医学会

キーワード

• rheumatoid arthritis
• Janus kinase
• kinase inhibitor
• tofacitinib

詳細情報

• CRID: 1390282680233547776
• NII論文ID: 130004482280
• DOI: 10.2492/inflammregen.31.349
• ISSN: 18808190
• ISSN: 18809693
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可